If you have searched for a pancreatic cancer drug lately, one name keeps appearing: daraxonrasib, sold in the US as Rasonque. Doctors and patient groups are calling it a breakthrough for a cancer that has seen very few advances in decades. This guide explains the FDA approval, the price and cost, the company behind it, the trials, and where this new medicine fits among treatment options. Show Image
Medical note: This article is for education only and is not individualized medical advice. Please read our medical disclaimer and discuss treatment decisions with your oncology team.
What Is Daraxonrasib?
Daraxonrasib is a once-daily oral medicine. It blocks the RAS family of proteins, and mutant forms of these proteins drive most pancreatic cancers. Because it does not target one specific mutation, it may act against several wild-type and mutant RAS proteins, which makes it a “pan-RAS” inhibitor and the first of its kind approved for any cancer. aacraacr
FDA Approval: A Breakthrough Pancreatic Cancer Drug
The FDA approved Rasonque on August 26, 2026, and the agency noted the decision came 6.5 months ahead of the user fee deadline. Before approval, the drug had earned breakthrough therapy and orphan drug designations, which is where the “breakthrough” label comes from. The FDA also used a priority voucher program that cut the usual 10-to-12-month review to about a month. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer +3
Who is the drug approved for?
The label covers adults with metastatic pancreatic adenocarcinoma whose cancer has progressed after at least one earlier systemic therapy, or who cannot receive multiagent systemic therapy. aacr
What is not approved yet?
Daraxonrasib is not approved as a first treatment for newly diagnosed patients. In November 2026, the maker and researchers released updated results on daraxonrasib combined with standard chemotherapy as a first treatment, a use the FDA has not approved. That combination received breakthrough designation, which can speed a future review but is not an approval. nacionale
The Company Behind the New Pancreatic Cancer Drug
The FDA granted the approval to Revolution Medicines, Inc., a California-based biotech company. Even before approval, more than 2,000 patients had received the drug through an expanded access program. fdaYahoo Finance
Daraxonrasib Trials: What the Evidence Shows
The approval rests on RASolute 302, a randomized, open-label, multicenter phase III trial of 500 patients whose cancer had progressed after one prior treatment. Here is how the two arms compared: aacr
| Measure | Daraxonrasib | Standard chemotherapy |
|---|---|---|
| Median overall survival | 13.2 months | 6.7 months |
| Median progression-free survival | 7.2 months | 3.6 months |
| Objective response rate | 30% | 11% |
These figures come from the overall trial population. The drug also lowered the risk of death by 60 percent. Dana-Farber’s Brian Wolpin, who led the pivotal study, described the results as the most significant therapeutic advance in metastatic pancreatic cancer in decades. Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough? +2
More trials are underway, including studies in earlier-stage treatment and combinations. Patient advocates encourage people to ask their care team about trial options. To learn how we check claims like these, see how we report and verify health news.
Daraxonrasib Price and Cost
Price (list price): The manufacturer’s wholesale acquisition cost is $39,800 per 30-day supply, or about $477,600 a year. medrxiv
Cost to patients: The list price is not necessarily what you pay. It is the drug’s list price, not what individual patients will necessarily owe. Some commercially insured patients can pay as little as $0 through copay assistance. Coverage problems are still real, though. Some patients have reported insurer denials because of the cost, so oncology teams advise starting financial navigation as soon as the drug is prescribed. FDA approves Rasonque for pancreatic cancer: When it’s available and cost +2
For context, one analysis estimated a common chemotherapy regimen at about $6,000–7,000 per month, making Rasonque roughly six to seven times more expensive. Substack
Is Daraxonrasib the Pancreatic Cancer Drug of Choice?
There is no single “drug of choice” for everyone. For people with previously treated metastatic disease, daraxonrasib is now a strong, evidence-backed option. For newly diagnosed patients, chemotherapy remains the standard approach until first-line results are reviewed. The Pancreatic Cancer Action Network advises patients not to delay treatment and to discuss every option with their healthcare team, including chemotherapy and clinical trials. pancan
Key Takeaways
- Daraxonrasib (Rasonque) is a new oral pancreatic cancer drug with FDA approval for previously treated metastatic disease.
- In trials, median survival nearly doubled compared with chemotherapy.
- The list price is about $39,800 per month, but actual cost to patients varies with insurance and assistance programs.
- First-line use is still under study and not yet approved.
Frequently Asked Questions
Is daraxonrasib FDA approved?
Yes. It was approved as Rasonque on August 26, 2026, for adults with previously treated metastatic pancreatic adenocarcinoma, or those who cannot receive multiagent therapy.
Which company makes daraxonrasib?
Revolution Medicines, Inc.
How much does this pancreatic cancer drug cost?
The list price is $39,800 per 30-day supply. What you pay depends on your insurance and available assistance programs.
Is daraxonrasib a cure?
No. In trials it extended survival and delayed progression, but it is not a cure.
Can newly diagnosed patients take it?
Not yet as an approved first treatment. Ask your oncologist about trials.
Want more plain-language updates on FDA decisions and new treatments? Browse our latest explained health news. Learn more about Healthy Golden Gems.
Sources and further reading: FDA press release on Rasonque · Pancreatic Cancer Action Network · AACR summary
Published: November 21, 2026
